|
1
|
Mennitto A, Verzoni E, Peverelli G, Alessi
A and Procopio G: Management of metastatic collecting duct
carcinoma: An encouraging result in a patient treated with
cabozantinib. Clin Genitourin Cancer. 16:e521–e523. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Orsola A, Trias I, Raventós CX, Español I,
Cecchini L and Orsola I: Renal collecting (Bellini) duct carcinoma
displays similar characteristics to upper tract urothelial cell
carcinoma. Urology. 65:49–54. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oudard S, Banu E, Vieillefond A, Fournier
L, Priou F, Medioni J, Banu A, Duclos B, Rolland F, Escudier B, et
al: Prospective multicenter phase II study of gemcitabine plus
platinum salt for metastatic collecting duct carcinoma: Results of
a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. J Urol.
177:1698–1702. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yin M, Wang W, Rosenberg J, Kaag M, Joshi
M, Holder S, Tuanquin L and Drabick JJ: Targeted therapy in
collecting duct carcinoma of the kidney: A case report and
literature review. Clin Genitourin Cancer. 14:e203–e236. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suarez C, Marmolejo D, Valdivia A,
Morales-Barrera R, Gonzalez M, Mateo J, Semidey ME, Lorente D,
Trilla E and Carles J: Update in collecting duct carcinoma: Current
aspects of the clinical and molecular characterization of an orphan
disease. Front Oncol. 12:9701992022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pepek J, Johnstone P and Jani A: Influence
of demographic factors on outcome of collecting duct carcinoma: A
surveillance, epidemiology, and end results (SEER) database
analysis. Clin Genitourin Cancer. 7:E24–E27. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chapman JR: The KDIGO clinical practice
guidelines for the care of kidney transplant recipients.
Transplantation. 89:644–645. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Truong LD and Shen SS: Immunohistochemical
diagnosis of renal neoplasms. Arch Pathol Lab Med. 135:92–109.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carvalho JC, Thomas DG, Mchugh JB, Shah RB
and Kunju LP: P63, CK7, PAX8 and INI-1: An optimal
immunohistochemical panel to distinguish poorly differentiated
urothelial cell carcinoma from high-grade tumours of the renal
collecting system. Histopathology. 60:597–608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rini B, McKiernan J and Chang S: Kidney.
Amin M: AJCC Cancer Staging Manual. 8th edition. New York:
Springer; pp. pp7392017
|
|
11
|
U.S. Department of Health and Human
Services, . Common Terminology Criteria for Adverse Events (CTCAE)
Version 5.0. November 27–2017.
|
|
12
|
Rimar KJ, Meeks JJ and Kuzel TM:
Anti-programmed death receptor 1 blockade induces clinical response
in a patient with metastatic collecting duct carcinoma. Clin
Genitourin Cancer. 14:e431–e434. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ezaki T, Matsumoto K, Morita S, Shinoda K,
Mizuno R, Kikuchi E and Oya M: A case of gemcitabine and cisplatin
chemotherapy in a patient with metastatic urothelial carcinoma
receiving hemodialysis. Clin Genitourin Cancer. 14:e413–e416. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang PY, Dai MS, Ho CL and Yao NS:
Administration of gemcitabine and cisplatin in cancer patients with
renal failure under hemodialysis. J BUON. 18:1058–1061.
2013.PubMed/NCBI
|
|
15
|
Kiani A, Köhne CH, Franz T, Passauer J,
Haufe T, Gross P, Ehninger G and Schleyer E: Pharmacokinetics of
gemcitabine in a patient with end-stage renal disease: Effective
clearance of its main metabolite by standard hemodialysis
treatment. Cancer Chemother Pharmacol. 51:266–270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Masumori N, Kunishima Y, Hirobe M,
Takeuchi M, Takayanagi A, Tsukamoto T and Itoh T: Measurement of
plasma concentration of gemcitabine and its metabolite dFdU in
hemodialysis patients with advanced urothelial cancer. Jpn J Clin
Oncol. 38:182–185. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Janus N, Thariat J, Boulanger H, Deray G
and Launay-Vacher V: Proposal for dosage adjustment and timing of
chemotherapy in hemodialyzed patients. Ann Oncol. 21:1395–403.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zahra MA, Taylor A, Mould G, Coles C,
Crawford R and Tan LT: Concurrent weekly cisplatin chemotherapy and
radiotherapy in a haemodialysis patient with locally advanced
cervix cancer. Clin Oncol. 20:6–11. 2008. View Article : Google Scholar
|
|
19
|
Horie S, Oya M, Nangaku M, Yasuda Y,
Komatsu Y, Yanagita M, Kitagawa Y, Kuwano H, Nishiyama H, Ishioka
C, et al: Guidelines for treatment of renal injury during cancer
chemotherapy 2016. Clin Exp Nephrol. 22:210–244. 2018. View Article : Google Scholar : PubMed/NCBI
|
